Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.886
Peer-review started: December 12, 2023
First decision: December 25, 2023
Revised: January 9, 2024
Accepted: March 6, 2024
Article in press: March 6, 2024
Published online: May 15, 2024
Processing time: 149 Days and 13.1 Hours
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are a growing health burden across a significant portion of the global patient population. However, these conditions seem to have disparate rates and outcomes between different ethnic populations. The combination of MASLD/MASH and type 2 diabetes increases the risk of hepatocellular carcinoma (HCC), and Hispanic patients experience the greatest burden, particularly those in South Texas.
To compare outcomes between Hispanic and non-Hispanic patients in the United States, while further focusing on the Hispanic population within Southeast Texas to determine whether the documented disparity in outcomes is a function of geographical circumstance or if there is a more widespread reason that all clinicians must account for in prognostic consideration.
This cohort analysis was conducted with data obtained from TriNetX, LLC (“TriNetX”), a global federated health research network that provides access to deidentified medical records from healthcare organizations worldwide. Two cohort networks were used: University of Texas Medical Branch (UTMB) hospital and the United States national database collective to determine whether disparities were related to geographic regions, like Southeast Texas.
This study findings revealed Hispanics/Latinos have a statistically significant higher occurrence of HCC, type 2 diabetes mellitus, and liver fibrosis/cirrhosis in both the United States and the UTMB Hispanic/Latino groups. All-cause mortality in Hispanics/Latinos was lower within the United States group and not statistically elevated in the UTMB cohort.
This would appear to support that Hispanic patients in Southeast Texas are not uniquely affected compared to the national Hispanic population.
Core Tip: We reviewed the outcome data between Hispanic and non-Hispanic patients diagnosed with metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis in both University of Texas Medical Branch (UTMB) and separately in a United States national cohort to determine if disparities in outcomes were confined to a geographically-defined region, i.e., Southeast Texas, or observed nationally. Outcomes included rates of all-cause mortality, hepatocellular carcinoma, type 2 diabetes mellitus, and liver fibrosis/cirrhosis between the Hispanic and non-Hispanic. Outcome disparities between Hispanic and non-Hispanic groups were observed in the UTMB and United States cohorts at similar rates in all outcomes with the exception of all-cause mortality in the UTMB cohort.